PREVACID(R) (lansopraxole)

TAP Pharmaceuticals

Approval Status
Approved April 1998

Treatment for


TAP Holdings received approval from the U.S. Food and Drug Administration (FDA) for PREVACID(R) (lansoprazole) Delayed-Release Capsules in the short-term treatment of Symptomatic GERD. The most common symptom of GERD is heartburn caused by the reflux of gastric juices from the stomach into the esophagus.

PREVACID is well tolerated. The most frequently reported adverse events included headache, abdominal pain and diarrhea.

PREVACID(R) (lansopraxole) Drug Information

The PREVACID(R) (lansopraxole) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top